Department of Pathology-Immunology and Paediatrics, Centre for Vaccinology, University Hospitals of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
PLoS One. 2012;7(7):e40428. doi: 10.1371/journal.pone.0040428. Epub 2012 Jul 27.
Memory responses require immune competence. We assessed the influence of priming with AS03-adjuvanted pandemic vaccine (Pandemrix®) on memory responses of HIV patients, kidney recipients (SOT) and healthy controls (HC).
Participants (HIV: 197, SOT: 53; HC: 156) were enrolled in a prospective study and 390/406 (96%) completed it. All had been primed in 2009/2010 with 1 (HC) or 2 (patients) doses of Pandemrix®, and were boosted with the 2010/2011 seasonal influenza vaccine. Geometric mean titres and seroprotection rates were measured 12 months after priming and 4 weeks after boosting. Primary and memory responses were directly compared in 191 participants (HCW: 69, HIV: 71, SOT: 51) followed during 2 consecutive seasons.
Most participants (HC: 77.8%, HIV: 77.6%, SOT: 66%) remained seroprotected at 12 months post-priming. Persisting A/09/H1N1 titers were high in HIV (100.2) and HC (120.1), but lower in SOT (61.4) patients. Memory responses reached higher titers in HIV (507.8) than in HC (253.5) and SOT (136.9) patients. Increasing age and lack of HAART reduced persisting and memory responses, mainly influenced by residual antibody titers. Comparing 2009/2010 and 2010/2011 titers in 191 participants followed for 2 seasons indicated lower post-2010/2011 titers in HC (240.2 vs 313.9), but higher titers in HIV (435.7 vs 338.0) and SOT (136 vs 90.3) patients.
Priming with 2 doses of Pandemrix® elicited persistent antibody responses and even stronger memory responses to non-adjuvanted seasonal vaccine in HIV patients than 1 dose in healthy subjects. Adjuvanted influenza vaccines may improve memory responses of immunocompromised patients.
ClinicalTrials.gov NCT01022905.
记忆反应需要免疫能力。我们评估了用 AS03 佐剂大流行性流感疫苗（Pandemrix®）对 HIV 患者、肾移植受者（SOT）和健康对照（HC）的记忆反应的影响。
参与者（HIV：197，SOT：53；HC：156）被纳入前瞻性研究，其中 406 人（96%）完成了研究。所有参与者均于 2009/2010 年接受过 1 剂（HC）或 2 剂（患者）Pandemrix®的基础免疫，并在 2010/2011 年接种了季节性流感疫苗加强针。在基础免疫后 12 个月和加强免疫后 4 周测量几何平均滴度和血清保护率。在连续两个季节随访的 191 名参与者（HCW：69，HIV：71，SOT：51）中直接比较了原发性和记忆性反应。
大多数参与者（HC：77.8%，HIV：77.6%，SOT：66%）在基础免疫后 12 个月仍保持血清保护。HIV（100.2）和 HC（120.1）中的 A/09/H1N1 滴度仍较高，但 SOT（61.4）患者较低。HIV（507.8）患者的记忆反应达到比 HC（253.5）和 SOT（136.9）患者更高的滴度。年龄增长和缺乏 HAART 降低了持续性和记忆性反应，主要受残留抗体滴度的影响。在 191 名连续两个季节随访的参与者中比较 2009/2010 年和 2010/2011 年的滴度表明，HC（240.2 对 313.9）的 2010/2011 年后滴度较低，但 HIV（435.7 对 338.0）和 SOT（136 对 90.3）患者的滴度较高。
用 2 剂 Pandemrix®进行基础免疫可在 HIV 患者中产生对非佐剂季节性疫苗的持续抗体反应，甚至比健康受试者中 1 剂产生更强的记忆反应。佐剂流感疫苗可能改善免疫功能低下患者的记忆反应。
ClinicalTrials.gov NCT01022905。
